|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4027 USD | +11.86% |
|
+6.87% | -87.98% |
| Nov. 06 | VYNE Therapeutics Q3 net loss narrows, strategic review ongoing | RE |
| Nov. 06 | VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 | CI |
Main competitors
| Dividend Yield (N) | Dividend Yield (N+1) | P/E (N) | Price to Book (N) | EV / Sales (N) | EV / EBITDA (N) | EV / EBIT (N) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | -0.58x | - | - | - | - | 13.4M | |
| -.--% | -.--% | 47.75x | 7.69x | 11.5x | 41.4x | 42.62x | 52.36B | |
| -.--% | -.--% | -32.55x | 65.04x | 82.63x | -36.52x | -36.11x | 42.8B | |
| 1.81% | 1.7% | 15.7x | 3.72x | 5.5x | 12.41x | 13.58x | 37.7B | |
| -.--% | -.--% | -23.11x | 1.05x | 3.05x | -8.34x | -6.59x | 22.18B | |
| -.--% | -.--% | 16.92x | 3.18x | 4.16x | 11.11x | 11.73x | 19.28B | |
| -.--% | -.--% | 26.92x | 2.49x | 5.28x | 14.63x | 18.22x | 17.01B | |
| -.--% | -.--% | -481.75x | 13.2x | 27.79x | 655.39x | -558.99x | 13.84B | |
| -.--% | -.--% | -13.26x | - | 166.41x | -25.95x | -12.92x | 13.29B | |
| -.--% | -.--% | -55.89x | 20.87x | 12.69x | -49.58x | -48x | 12.6B | |
| -.--% | -.--% | -177.72x | 21.56x | 42.12x | -171.05x | -151.14x | 12.12B | |
| -.--% | -.--% | 16.33x | 4.28x | 4.55x | 11.29x | 12.69x | 11.2B | |
| -.--% | -.--% | -19.57x | 16.25x | 19.98x | -30.38x | -18.95x | 8.78B | |
| -.--% | -.--% | -17.92x | 8.51x | - | -18.42x | -17.81x | 7.97B | |
| -.--% | -.--% | -9.81x | -14.98x | 86.46x | -12x | -11.7x | 7.58B | |
| Average | 0.13% | 0.12% | -47.24x | 11.76x | 36.32x | 28.14x | -54.53x | 18.58B | |
| Weighted average by Cap. | 0.24% | 0.23% | -28.48x | 16.22x | 32.25x | 25.12x | -32.34x |
- Stock Market
- Equities
- VYNE Stock
- Sector VYNE Therapeutics Inc.
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
